180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. This action is intended to satisfy the NASDAQ's minimum bid price requirement for continued listing. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to about 0.6 million. No fractional shares will be issued; stockholders who would have received a fractional share will instead receive one whole share. The company's common stock will continue to trade on the NASDAQ under the symbol 'ATNF'. Prior to the reverse stock split, the company's stock was trading at $0.195 per share as of February 27, 2024. Additionally, the company has filed a prospectus supplement that updates...Show More

180 Life Sciences Corp. has announced a 1-for-19 reverse stock split of its common stock, effective as of 12:01 A.M. Eastern Time on February 28, 2024. This action is intended to satisfy the NASDAQ's minimum bid price requirement for continued listing. The reverse stock split will reduce the number of outstanding shares from approximately 11.3 million to about 0.6 million. No fractional shares will be issued; stockholders who would have received a fractional share will instead receive one whole share. The company's common stock will continue to trade on the NASDAQ under the symbol 'ATNF'. Prior to the reverse stock split, the company's stock was trading at $0.195 per share as of February 27, 2024. Additionally, the company has filed a prospectus supplement that updates and amends previous filings with the SEC, including information on the reverse stock split and recent Current Reports on Form 8-K. In other events, the company won a Motion for Partial Summary Judgment in a lawsuit, which obligates two insurers to advance defense costs related to SEC subpoenas to former executives, with a trial scheduled for May 12, 2025.